Long title
A randomized, open-label, Phase 2 study evaluating lymphodepletion with fludarabine (F), cyclophosphamide (C), and ALLO-647 (A) vs FC alone, in subjects with R/R LBCL receiving ALLO-501A allogeneic CAR T cell therapy
Date receipt dossier
EudraCT number
2023-503830-27
Company / Sponsor
Allogene therapeutics
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
diffuse large B-cell lymphoma (DLBCL)
Therapeutic approach
Immunotherapy
Genetic modification
CD19 CAR + knockouts CD52 and TRAC via TALEN technology
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Allogeneic T cellstransduced with lentiviral vectors expressing CD19 CAR; TRAC (T Cell Receptor Alpha Constant) and CD52 knockout genes by TALEN technology
Route of administration
Intravenous
Locations in Belgium
UZ Leuven, UZ Brussel, Cliniques universitaires Saint-Luc, ZNA
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
ALLO-501A